Ovarian Reserve Testing for Infertility in Cancer Survivors
Trial Summary
Will I have to stop taking my current medications?
If you are taking birth control pills, patches, or a vaginal ring, you will need to stop using them for 3 months during the trial. The protocol does not specify about other medications, so it's best to discuss with the trial team.
What data supports the effectiveness of the treatment Basal and Provocative Ovarian Reserve Testing, Blood Draws, Pelvic Ultrasounds, Recombinant FSH for infertility in cancer survivors?
Ovarian reserve tests, which include blood tests and ultrasounds, help estimate a woman's remaining egg supply and her response to fertility treatments. These tests are particularly useful for cancer survivors, as they can indicate changes in ovarian function due to cancer treatments, although more research is needed to fully understand their predictive value for fertility outcomes.12345
Is ovarian reserve testing safe for cancer survivors?
How is ovarian reserve testing unique for infertility in cancer survivors?
Ovarian reserve testing is unique for infertility in cancer survivors because it helps assess the impact of cancer treatments on a woman's remaining egg supply and fertility potential. This testing is crucial as cancer treatments can significantly affect ovarian function, and understanding the ovarian reserve can guide fertility preservation and treatment decisions.12389
What is the purpose of this trial?
Young adult cancer survivors constitute an under served population to whom fertility potential is particularly important. For female young adult patients, cancer treatment such as alkylating chemotherapy are toxic to the finite number of eggs they have, resulting in risks of infertility and premature menopause related to ovarian failure. Reproductive issues are a major concern for young cancer survivors, but one that is understudied. Young cancer survivors have few tools to measure post-treatment ovarian reserve, or the quantity and quality of remaining eggs4. Accurate determination of ovarian reserve and fertility potential would not only be an important research tool, but also directly impact clinical management. The purpose of this study is to test if basal and provocative ovarian reserve testing can predict return of menses in female young adult cancer survivors, to compare basal and provocative ovarian reserve testing results between female young adult cancer survivors and healthy controls, and to compare basal and provocative ovarian reserve testing results between female young adult cancer survivors on and off of combined estrogen and progesterone hormone products.Participants will be asked to keep track of their periods over three months. If a participant is taking birth control pills, patches, or vaginal ring, they will asked to come off the birth control for 3 months. Participants will also be asked to undergo ovarian reserve testing by blood draws and pelvic ultrasounds at the start and end of the 3 months.
Research Team
H. Irene Su, MD MSCE
Principal Investigator
UC San Diego
Eligibility Criteria
This trial is for young adult female cancer survivors who are postmenarchal, have at least one ovary and an intact uterus, and have undergone gonadotoxic therapy like chemotherapy or irradiation. They should be one year past their treatment completion. Those with estrogen receptor positive cancers cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline Testing
Participants undergo ovarian reserve testing by blood draws and pelvic ultrasounds
Monitoring
Participants track their periods over three months and may come off birth control
Follow-up
Participants are monitored for return of menses and ovarian reserve
Treatment Details
Interventions
- Basal and Provocative Ovarian Reserve Testing
- Blood Draws
- Pelvic Ultrasounds
- Recombinant FSH
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, San Diego
Lead Sponsor